/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company headquartered in Foster City, California, known for discovering, developing, and commercializing innovative medicines that address serious unmet medical needs in areas such as HIV/AIDS, viral hepatitis, COVID-19, oncology, and inflammation. Gilead Sciences has a market cap of around $155 billion, reflecting its position as a significant player in the healthcare and biotechnology sectors.
The company is set to announce its fiscal Q4 earnings results soon. Ahead of the event, analysts expect GILD to report a profit of $1.86 per share, down 2.1% from $1.90 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three of the past four quarters and missed on another occasion.